Krishna Institute of Medical Sciences Stock Price - ₹767.85 | Healthcare Services

‌
‌
‌

Company insights, generated from the most recent coverage.

Trading at 163x PE with ₹31,757 Cr market cap — premium valuation reflects high-growth hospital chain thesis, still ~9% below 52-week high.
Signed O&M agreement for 250-bed Arete Hospital in Hyderabad — expands network capacity without heavy capex, reinforcing asset-light growth strategy.
KIMS denied acquisition talks with Renova Hospitals; market viewed denial as positive relief, avoiding potentially dilutive or expensive deal.

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Revenue and bed capacity are expanding rapidly, but profitability and margins are under pressure from aggressive growth and rising operational costs.

Total revenue grows from ₹878.7 Cr in Q1 FY26 to ₹11,959 Cr in Q1 FY27, driven by steady patient volume increases.

PAT margin compresses from 9.7% in Q1 FY26 to 3.1% in Q1 FY27, as expansion costs outpace profit growth.

Bed capacity expands from 5,499 to 7,459 over five quarters, adding nearly 2,000 new beds to the network.

Basic EPS halves from ₹2.0 to ₹1.04 over five quarters, reflecting diluted earnings per share.

Average revenue per patient rises from ₹1,53,094 to ₹1,63,573 from Q1 FY26 to Q1 FY27, showing consistent pricing power.

Telangana occupancy drops from 56.2% to 41.1% in Q1 FY27, as new beds take time to fill.

Kerala occupancy climbs from 34.2% to 46.0% over the period, while EBITDA margin turns positive at 9.7% after starting at -6.9%.

Consolidated EBITDA swings from ₹199.7 Cr to -₹50.8 Cr over the period, weighed down by lease expenses and new facility ramp-up costs.

Average length of stay falls from 3.56 to 3.47 days across five quarters, indicating faster patient discharge and better bed turnover.

‌
‌
‌

In the news

Investec sets ₹1,000 target for KIMS stock with 32.7% upside

KIMS to operate 250-bed Hyderabad hospital under 5-year deal

KIMS Issues 77.02 Lakh Convertible Warrants for ₹150 Crore Funding

KIMS Q1 profit drops 47% despite strong volume growth

5 Stocks Dominate India's Top Smallcap Funds with ₹8,000 Cr Holdings

Top stocks to watch: Wipro, HDFC Bank, Power Grid today

Corporate Developments: Dr Reddy's, Adani Green, JSW Energy, KIMS, Nestlé, NLC India, LIC

Four Pharma Stocks in Focus: Licensing Deals & Fund Raises

KIMS approves ₹599.99 cr warrant issue to promoters at ₹779/warrant

KIMS gains 1.31% as board mulls fundraising plan on June 13

5 Stocks to Buy: KIMS, Endurance, Kalpataru, Godfrey Phillips

Regional Hospital Stocks Show Mixed Q1 2026 Results Amid Growth

KIMS Stock Breaks Triangle Pattern, Targets ₹900-920

KIMS board approves ₹1,500 crore equity fundraise

Krishna Institute of Medical Sciences